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Supplementary Materials and Methods 
DNA isolation from FFPE tumor samples 
Tumour areas containing >80% tumour nuclei were chosen for DNA isolation, macrodissected from unstained 10 µm sections, and incubated in the presence of 
1ml limonene (30 min, 60°C, 1,000 rpm). Deparaffinized tissues were rehydrated (consecutive washing with 98% and 70% ethanol) and incubated (8 h, 60°C) in 
200 µl of lysis buffer (50 mM Tris-HCl, pH 8.4, 1 mM EDTA, 0.5% [v/v] Tween®20 and 2 mg/ml proteinase K [Carl Roth, Karlsruhe, Germany]). Another 20 µl of 
Proteinase K (20 mg/ml) was added. Following incubation (16 h, 60°C, 1,000 rpm), 200 µl of tissue lysate was mixed with 250 µl of binding buffer (6 M guanidinium 
thiocyanate, 0.1 M Tris, pH 7.5), 250 µl of ethanol, transferred onto a NucleoSpin Extract II spin column (Macherey & Nagel, Dueren, Germany), and centrifuged 
(3 min, 14,000x g). The bound DNA was washed twice with 700 µl of wash buffer (150 mM Tris pH 7.4, 85% ethanol). The wash buffer was removed (1 min, 
14,000x g). A total of 50 μl of water was added, incubated for 1 min, and the DNA was eluted (1 min, 14,000x g). The DNA concentration was quantified using a 
Nanodrop® ND-1000 photometer (NanoDrop Technologies, Wilmington, DE, USA). 
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Supplementary Figure 1: A) Rare BRCA1/2 germline variants identified in the overall study sample of 488 patients with OC. The majority of individuals (307, 62.9%) carried no 
rare germline variant in the BRCA1/2 genes; 157 individuals carried one (32.2%), 21 individuals carried two (4.3%), and three individuals carried three rare germline variants 
(0.6%). B) BRCA1/2 genotypes of the 181 patients with rare BRCA1/2 variants. 79 patients carried class 4/5 variants only. Of those, one patient carried a combination of one 
BRCA1 and one BRCA2 class 4/5 variant. 13 patients carried one class 4/5 BRCA1/2 variant in addition to one class 1/2 variant; another patient carried one class 4/5 variant, one 
class 3, and one class 1/2 variant. 67 patients carried class 1/2 variants only (60 with one variant, five with two, and two with three variants). 21 patients carried class 3 variants 
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Supplementary Table 1: Characteristics of the 488 individuals with ovarian cancer included in this investigation. Of the 488 patients, 266 were enrolled at primary diagnosis of 
ovarian cancer and 222 were enrolled with recurrent ovarian cancer.   
 
 
Supplementary Table 2: Rare germline variants in the BRCA1 and BRCA2 genes observed in 488 OC patients. For each variant, the results of paired NGS analyses of the DNA sample derived 
from blood and the DNA sample derived from the corresponding tumour are shown, i.e. the number of reads showing the variant allele and the number of reads showing reference allele. 
ExAC % = Frequency of the germline variant in percent according to the Exome Aggregation Consortium (ExAC) in a dataset of individuals of European, non-Finnish ancestry, excluding samples 
from The Cancer Genome Atlas (TCGA). This dataset comprises a total of 27,173 samples that were analyzed by whole-exome sequencing. * = Fisher’s Exact test was applied to assess the 
significance level of deviating variant fractions in blood vs tumour samples, with p values <0.05 considered significant after correction for multiple testing using the Benjamini-Hochberg 
approach. 




















change P-Value * 
Class 4/5 variants 
P32 17 41245210 BRCA1 NM_007294.3 c.2338C>T p.(Gln780*) 0.0000 507 507 0.50 643 71 0.90 1.80 0.00000 
P51 17 41223242 BRCA1 NM_007294.3 c.4689C>G p.(Tyr1563*) 0.0000 409 480 0.46 685 121 0.85 1.85 0.00000 
P48 17 41226488 BRCA1 NM_007294.3 c.4533_4534del p.(His1511Glnfs*) 0.0000 256 288 0.47 1363 260 0.84 1.79 0.00000 
P63 17 41209079 BRCA1 NM_007294.3 c.5266dup p.(Gln1756Profs*74) 0.0166 258 315 0.45 593 139 0.81 1.80 0.00000 
Age at ovarian cancer diagnosis (mean, range) 58 years, 16-93 years 
Histological subtypes (% of the overall study sample)  
- High grade serous 382 (78.3) 
- High grade endometrioid 22 (4.5) 
- Serous/papillary, grade unknown 20 (4.1) 
- Low grade serous 17 (3.5) 
- Mucinous 8 (1.6) 
- Low grade endometrioid 7 (1.4) 
- Clear cell 6 (1.2) 
- Other/unspecified 19 (3.9) 
- Missing 7 (1.4) 
Tumour grade (% of the overall study sample)  
- G1 29 (5.9) 
- G2 69 (14.1) 
- G3 355 (72.7) 
- G4 6 (1.2) 
- Not specified 29 (5.9) 
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P60 17 41215362 BRCA1 NM_007294.3 c.5177_5180del p.(Arg1726Lysfs*3) 0.0000 212 269 0.44 602 150 0.80 1.82 0.00000 
P476 13 32905140 BRCA2 NM_000059.3 c.771_775del p.(Asn257fs) 0.0000 243 310 0.44 300 53 0.85 1.93 0.00000 
P42 17 41243843 BRCA1 NM_007294.3 c.3700_3704del p.(Val1234fs) 0.0000 446 523 0.46 562 177 0.76 1.65 0.00000 
P54 17 41222994 BRCA1 NM_007294.3 c.4936del p.(Val1646Serfs*12) 0.0000 294 306 0.49 633 148 0.81 1.65 0.00000 
P31 17 41245210 BRCA1 NM_007294.3 c.2338C>T p.(Gln780*) 0.0000 304 329 0.48 1091 364 0.75 1.56 0.00000 
P30 17 41245591 BRCA1 NM_007294.3 c.1953_1956del p.(Lys653fs) 0.0000 520 611 0.46 397 125 0.76 1.65 0.00000 
P26 17 41245861 BRCA1 NM_007294.3 c.1687C>T p.(Gln563*) 0.0074 340 353 0.49 594 168 0.78 1.59 0.00000 
P84 13 32912940 BRCA2 NM_000059.3 c.4449del p.(Asp1484fs) 0.0000 134 139 0.49 612 108 0.85 1.73 0.00000 
P44 17 41243776 BRCA1 NM_007294.3 c.3770_3771del p.(Glu1257fs) 0.0018 281 316 0.47 335 79 0.81 1.72 0.00000 
P65 17 41209079 BRCA1 NM_007294.3 c.5266dup p.(Gln1756Profs*74) 0.0166 431 505 0.46 460 161 0.74 1.61 0.00000 
P10 17 41276080 BRCA1 NM_007294.3 c.34C>T p.(Gln12*) 0.0000 110 110 0.50 482 66 0.88 1.76 0.00000 
P27 17 41245861 BRCA1 NM_007294.3 c.1687C>T p.(Gln563*) 0.0074 282 319 0.47 487 154 0.76 1.62 0.00000 
P18 17 41258504 BRCA1 NM_007294.3 c.181T>G p.(Cys61Gly) 0.0056 146 179 0.45 220 36 0.86 1.91 0.00000 
P95 13 32936830 BRCA2 NM_000059.3 c.7976G>A p.(Arg2659Lys) 0.0000 175 189 0.48 483 121 0.80 1.67 0.00000 
P24 17 41246355 BRCA1 NM_007294.3 c.1193C>G p.(Ser398*) 0.0000 290 314 0.48 494 165 0.75 1.56 0.00000 
P19 17 41258473 BRCA1 NM_007294.3 c.212G>C p.(Arg71Thr) 0.0000 190 206 0.48 183 27 0.87 1.81 0.00000 
P90 13 32914174 BRCA2 NM_000059.3 c.5682C>G p.(Tyr1894*) 0.0000 219 228 0.49 288 63 0.82 1.67 0.00000 
P57 17 41215957 BRCA1 NM_007294.3 c.5084_5085del p.(Phe1695Cysfs*3) 0.0000 109 118 0.48 553 121 0.82 1.71 0.00000 
P37 17 41244280 BRCA1 NM_007294.3 c.3268C>T p.(Gln1090*) 0.0000 238 238 0.50 462 138 0.77 1.54 0.00000 
P16 17 41258504 BRCA1 NM_007294.3 c.181T>G p.(Cys61Gly) 0.0056 99 162 0.38 315 117 0.73 1.92 0.00000 
P68 17 41209079 BRCA1 NM_007294.3 c.5266dup p.(Gln1756Profs*74) 0.0166 106 141 0.43 224 53 0.81 1.88 0.00000 
P92 13 32914437 BRCA2 NM_000059.3 c.5946del p.(Ser1982fs) 0.0388 225 217 0.51 138 17 0.89 1.75 0.00000 
P21 17 41256182 BRCA1 NM_007294.3 c.397del p.(Arg133fs) 0.0000 297 309 0.49 366 122 0.75 1.53 0.00000 
P40 17 41244056 BRCA1 NM_007294.3 c.3481_3491del p.(Glu1161fs) 0.0000 244 453 0.35 221 130 0.63 1.80 0.00000 
P53 17 41222997 BRCA1 NM_007294.3 c.4932_4933dup p.(Arg1645Lysfs*14) 0.0000 435 490 0.47 402 181 0.69 1.47 0.00000 
P29 17 41245504 BRCA1 NM_007294.3 c.2043dup p.(Asn682fs) 0.0000 110 140 0.44 623 230 0.73 1.66 0.00000 
P96 13 32954272 BRCA2 NM_000059.3 c.9253dup p.(Thr3085fs) 0.0000 254 350 0.42 151 50 0.75 1.79 0.00000 
P17 17 41258504 BRCA1 NM_007294.3 c.181T>G p.(Cys61Gly) 0.0056 68 95 0.42 177 42 0.81 1.93 0.00000 
P82 13 32912337 BRCA2 NM_000059.3 c.3847_3848del p.(Val1283fs) 0.0225 202 246 0.45 407 183 0.69 1.53 0.00000 
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P79 13 32911322 BRCA2 NM_000059.3 c.2830A>T p.(Lys944*) 0.0000 273 296 0.48 113 23 0.83 1.73 0.00000 
P59 17 41215391 BRCA1 NM_007294.3 c.5153-2del p.(?) 0.0000 128 163 0.44 325 127 0.72 1.64 0.00000 
P94 13 32936731 BRCA2 NM_000059.3 c.7877G>A p.(Trp2626*) 0.0000 324 324 0.50 464 199 0.70 1.40 0.00000 
P73 17 41209079 BRCA1 NM_007294.3 c.5266dup p.(Gln1756Profs*74) 0.0166 400 451 0.47 414 213 0.66 1.40 0.00000 
P50 17 41223242 BRCA1 NM_007294.3 c.4689C>G p.(Tyr1563*) 0.0000 251 241 0.51 167 44 0.79 1.55 0.00000 
P67 17 41209079 BRCA1 NM_007294.3 c.5266dup p.(Gln1756Profs*74) 0.0166 220 268 0.45 491 264 0.65 1.44 0.00000 
P91 13 32914437 BRCA2 NM_000059.3 c.5946del p.(Ser1982fs) 0.0388 464 503 0.48 539 303 0.64 1.33 0.00000 
P33 17 41245072 BRCA1 NM_007294.3 c.2475del p.(Asp825fs) 0.0000 148 143 0.51 474 166 0.74 1.45 0.00000 
P45 17 41243455 BRCA1 NM_007294.3 c.4093T>G p.(Leu1365Val) 0.0000 250 250 0.50 513 231 0.69 1.38 0.00000 
P14 17 41258504 BRCA1 NM_007294.3 c.181T>G p.(Cys61Gly) 0.0056 190 263 0.42 117 45 0.72 1.71 0.00000 
P34 17 41245032 BRCA1 NM_007294.3 c.2515del p.(His839fs) 0.0000 597 646 0.48 352 189 0.65 1.35 0.00000 
P70 17 41209079 BRCA1 NM_007294.3 c.5266dup p.(Gln1756Profs*74) 0.0166 249 281 0.47 440 226 0.66 1.40 0.00000 
P61 17 41215348 BRCA1 NM_007294.3 c.5193+1del p.(?) 0.0000 190 222 0.46 136 45 0.75 1.63 0.00000 
P72 17 41209079 BRCA1 NM_007294.3 c.5266dup p.(Gln1756Profs*74) 0.0166 470 510 0.48 248 117 0.68 1.42 0.00000 
P41 17 41243843 BRCA1 NM_007294.3 c.3700_3704del p.(Val1234fs) 0.0000 295 375 0.44 301 176 0.63 1.43 0.00000 
P13 17 41258504 BRCA1 NM_007294.3 c.181T>G p.(Cys61Gly) 0.0056 97 133 0.42 54 9 0.86 2.05 0.00000 
P89 13 32914174 BRCA2 NM_000059.3 c.5682C>G p.(Tyr1894*) 0.0000 239 270 0.47 725 426 0.63 1.34 0.00000 
P25 17 41245927 BRCA1 NM_007294.3 c.1621C>T p.(Gln541*) 0.0000 120 130 0.48 356 152 0.70 1.46 0.00000 
P86 13 32913829 BRCA2 NM_000059.3 c.5338del p.(Glu1780fs) 0.0000 120 130 0.48 356 153 0.70 1.46 0.00000 
P77 13 32907418 BRCA2 NM_000059.3 c.1805del p.(Gly602fs) 0.0000 377 409 0.48 208 102 0.67 1.40 0.00000 
P78 13 32910889 BRCA2 NM_000059.3 c.2399dup p.(Asn801fs) 0.0000 189 231 0.45 257 139 0.65 1.44 0.00000 
P22 17 41246432 BRCA1 NM_007294.3 c.1116G>A p.(Trp372*) 0.0000 314 327 0.49 140 55 0.72 1.47 0.00000 
P87 13 32913987 BRCA2 NM_000059.3 c.5496dup p.(Asn1833fs) 0.0000 208 225 0.48 104 37 0.74 1.54 0.00000 
P46 17 41234567 BRCA1 NM_007294.3 c.4210del p.(Leu1404fs) 0.0000 425 442 0.49 319 179 0.64 1.31 0.00000 
P97 13 32972315 BRCA2 NM_000059.3 c.9666del p.(Cys3222fs) 0.0018 302 302 0.50 154 66 0.70 1.40 0.00000 
P62 17 41209079 BRCA1 NM_007294.3 c.5266dup p.(Gln1756Profs*74) 0.0166 113 138 0.45 163 80 0.67 1.49 0.00000 
P56 17 41219625 BRCA1 NM_007294.3 c.5074G>C p.(Asp1692His) 0.0018 213 174 0.55 123 37 0.77 1.40 0.00000 
P11 17 41276044 BRCA1 NM_007294.3 c.68_69del p.(Glu23fs) 0.0406 148 148 0.50 137 53 0.72 1.44 0.00000 
P474 17 41245861 BRCA1 NM_007294.3 c.1687C>T p.(Gln563*) 0.0074 382 397 0.49 383 235 0.62 1.27 0.00000 
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P15 17 41258504 BRCA1 NM_007294.3 c.181T>G p.(Cys61Gly) 0.0000 102 111 0.48 440 226 0.66 1.38 0.00001 
P38 17 41244056 BRCA1 NM_007294.3 c.3481_3491del p.(Glu1161fs) 0.0000 85 146 0.37 653 579 0.53 1.43 0.00002 
P85 13 32913457 BRCA2 NM_000059.3 c.4965C>G p.(Tyr1655*) 0.0000 275 253 0.52 419 226 0.65 1.25 0.00003 
P12 17 41276047 BRCA1 NM_007294.3 c.66dup p.(Glu23fs) 0.0000 87 84 0.51 153 57 0.73 1.43 0.00004 
P49 17 41223242 BRCA1 NM_007294.3 c.4689C>G p.(Tyr1563*) 0.0000 264 335 0.44 310 234 0.57 1.30 0.00005 
P76 13 32907111 BRCA2 NM_000059.3 c.1499del p.(Gly500fs) 0.0000 175 197 0.47 114 56 0.67 1.43 0.00005 
P69 17 41209079 BRCA1 NM_007294.3 c.5266dup p.(Gln1756Profs*74) 0.0166 105 145 0.42 160 102 0.61 1.45 0.00006 
P52 17 41222997 BRCA1 NM_007294.3 c.4932_4933dup p.(Arg1645Lysfs*14) 0.0000 120 130 0.48 437 257 0.63 1.31 0.00014 
P75 17 41197784 BRCA1 NM_007294.3 c.5503C>T p.(Arg1835*) 0.0000 406 345 0.54 315 170 0.65 1.20 0.00045 
P28 17 41245670 BRCA1 NM_007294.3 c.1874_1877dup p.(Val627fs) 0.0000 113 138 0.45 271 188 0.59 1.31 0.00082 
P20 17 41256985 BRCA1 NM_007294.3 c.213-12A>G p.(?) 0.0000 112 137 0.45 57 27 0.68 1.51 0.00106 
P66 17 41209079 BRCA1 NM_007294.3 c.5266dup p.(Gln1756Profs*74) 0.0166 517 584 0.47 423 360 0.54 1.15 0.00743 
P93 13 32920978 BRCA2 NM_000059.3 c.6952C>T p.(Arg2318*) 0.0000 163 225 0.42 386 370 0.51 1.21 0.01077 
P74 17 41199683 BRCA1 NM_007294.3 c.5444G>A p.(Trp1815*) 0.0000 236 245 0.49 396 298 0.57 1.16 0.01927 
P36 17 41244439 BRCA1 NM_007294.3 c.3108dup p.(Lys1037fs) 0.0000 117 131 0.47 402 304 0.57 1.21 0.02414 
P47 17 41234556 BRCA1 NM_007294.3 c.4222C>T p.(Gln1408*) 0.0000 231 261 0.47 461 393 0.54 1.15 0.03756 
P64 17 41209079 BRCA1 NM_007294.3 c.5266dup p.(Gln1756Profs*74) 0.0166 222 282 0.44 319 306 0.51 1.16 0.04923 
P35 17 41244526 BRCA1 NM_007294.3 c.3018_3021del p.(His1006fs) 0.0000 290 355 0.45 243 233 0.51 1.13 0.11470 
P81 13 32912337 BRCA2 NM_000059.3 c.3847_3848del p.(Val1283fs) 0.0225 294 294 0.50 198 155 0.56 1.12 0.19348 
P58 17 41215947 BRCA1 NM_007294.3 c.5096G>A p.(Arg1699Gln) 0.0056 258 229 0.53 125 84 0.60 1.13 0.27217 
P478 13 32914209 BRCA2 NM_000059.3 c.5722_5723del p.(Leu1908fs) 0.0000 390 422 0.48 245 311 0.44 0.92 0.35063 
P477 13 32911371 BRCA2 NM_000059.3 c.2880del p.(Lys960fs) 0.0000 185 209 0.47 58 87 0.40 0.85 0.39229 
P71 17 41209079 BRCA1 NM_007294.3 c.5266dup p.(Gln1756Profs*74) 0.0166 277 338 0.45 245 256 0.49 1.09 0.45857 
P23 17 41246420 BRCA1 NM_007294.3 c.1127del p.(Asn376fs) 0.0000 548 643 0.46 131 131 0.50 1.09 0.54472 
P55 17 41222948 BRCA1 NM_007294.3 c.4964_4982del p.(Ser1655Tyrfs*16) 0.0018 132 268 0.33 169 393 0.30 0.91 0.76483 
P475 17 41243788 BRCA1 NM_007294.3 c.3756_3759del p.(Ser1253fs) 0.0000 447 504 0.47 411 427 0.49 1.04 0.83360 
P37 13 32914758 BRCA2 NM_000059.3 c.6267_6269delinsC p.(Glu2089Aspfs*2) 0.0000 131 213 0.38 238 342 0.41 1.08 0.85183 
P88 13 32914137 BRCA2 NM_000059.3 c.5645C>A p.(Ser1882*) 0.0037 116 126 0.48 458 440 0.51 1.06 0.88660 
P80 13 32911755 BRCA2 NM_000059.3 c.3264dup p.(Gln1089fs) 0.0000 241 231 0.51 196 205 0.49 0.96 1.10306 
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P43 17 41243788 BRCA1 NM_007294.3 c.3756_3759del p.(Ser1253fs) 0.0000 108 143 0.43 302 369 0.45 1.05 1.29954 
P39 17 41244056 BRCA1 NM_007294.3 c.3481_3491del p.(Glu1161fs) 0.0000 196 307 0.39 350 571 0.38 0.97 1.41640 
P83 13 32912940 BRCA2 NM_000059.3 c.4449del p.(Asp1484fs) 0.0000 388 438 0.47 118 134 0.47 1.00 1.84878 
Class 3 variants 
P241 17 41245975 BRCA1 NM_007294.3 c.1573G>A p.(Val525Ile) 0.0000 420 456 0.48 51 463 0.10 0.21 0.00000 
P338 17 41244094 BRCA1 NM_007294.3 c.3454G>A p.(Asp1152Asn) 0.0000 378 444 0.46 74 452 0.14 0.30 0.00000 
P322 13 32911181 BRCA2 NM_000059.3 c.2689G>A p.(Glu897Lys) 0.0000 124 124 0.50 475 47 0.91 1.82 0.00000 
P404 13 32914392 BRCA2 NM_000059.3 c.5900A>G p.(Lys1967Arg) 0.0000 232 284 0.45 528 149 0.78 1.73 0.00000 
P271 17 41209133 BRCA1 NM_007294.3 c.5213G>A p.(Gly1738Glu) 0.0000 218 255 0.46 297 56 0.84 1.83 0.00000 
P338 13 32936722 BRCA2 NM_000059.3 c.7868A>G p.(His2623Arg) 0.0000 343 316 0.52 340 70 0.83 1.60 0.00000 
P188 17 41215379 BRCA1 NM_007294.3 c.5161_5163del p.(Gln1721del) 0.0000 101 134 0.43 298 66 0.82 1.91 0.00000 
P127 13 32907520 BRCA2 NM_000059.3 c.1905T>G p.(Asp635Glu) 0.0000 130 165 0.44 231 77 0.75 1.70 0.00000 
P98 17 41244094 BRCA1 NM_007294.3 c.3454G>A p.(Asp1152Asn) 0.0000 471 600 0.44 16 95 0.14 0.32 0.00000 
P156 13 32900240 BRCA2 NM_000059.3 c.433_435del p.(Val145del) 0.0018 162 182 0.47 351 165 0.68 1.45 0.00000 
P227 13 32953474 BRCA2 NM_000059.3 c.8775G>C p.(Gln2925His) 0.0000 228 238 0.49 324 153 0.68 1.39 0.00000 
P245 17 41215387 BRCA1 NM_007294.3 c.5156T>G p.(Val1719Gly) 0.0000 120 130 0.48 281 145 0.66 1.38 0.00002 
P146 17 41244466 BRCA1 NM_007294.3 c.3082C>T p.(Arg1028Cys) 0.0037 117 132 0.47 739 473 0.61 1.30 0.00016 
P237 13 32930614 BRCA2 NM_000059.3 c.7491_7493del p.(Lys2498del) 0.0000 179 258 0.41 123 302 0.29 0.71 0.00076 
P171 13 32918701 BRCA2 NM_000059.3 c.6848C>T p.(Pro2283Leu) 0.0000 191 263 0.42 200 184 0.52 1.24 0.01158 
P241 13 32972525 BRCA2 NM_000059.3 c.9875C>T p.(Pro3292Leu) 0.0018 521 521 0.50 250 181 0.58 1.16 0.01551 
P173 13 32912357 BRCA2 NM_000059.3 c.3865A>G p.(Lys1289Glu) 0.0000 300 366 0.45 479 479 0.50 1.11 0.13594 
P120 13 32911794 BRCA2 NM_000059.3 c.3302A>G p.(His1101Arg) 0.0000 136 112 0.55 135 82 0.62 1.13 0.26637 
P487 17 41245699 BRCA1 NM_007294.3 c.1846_1848del p.(Ser616del) 0.0018 104 143 0.42 269 440 0.38 0.90 0.56528 
P415 13 32953965 BRCA2 NM_000059.3 c.9032T>C p.(Leu3011Pro) 0.0000 198 190 0.51 88 70 0.56 1.10 0.73957 
P52 13 32915105 BRCA2 NM_000059.3 c.6613G>A p.(Val2205Met) 0.0056 118 122 0.49 263 252 0.51 1.04 1.27614 
P386 17 41228555 BRCA1 NM_007294.3 c.4434G>T p.(Glu1478Asp) 0.0000 282 306 0.48 323 336 0.49 1.02 1.41127 
P453 17 41226518 BRCA1 NM_007294.3 c.4505C>A p.(Pro1502Gln) 0.0000 480 480 0.50 198 206 0.49 0.98 1.45329 
P167 13 32906831 BRCA2 NM_000059.3 c.1216_1219delinsACCG 
p.(Ala406_Gln407del
insThrGlu) 0.0018 322 349 0.48 340 369 0.48 1.00 1.82212 
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Class 1/2 variants 
P274 17 41245027 BRCA1 NM_007294.3 c.2521C>T p.(Arg841Trp) 0.2099 506 506 0.50 201 1237 0.14 0.28 0.00000 
P218 17 41226488 BRCA1 NM_007294.3 c.4535G>T p.(Ser1512Ile) 0.3129 492 555 0.47 12 404 0.03 0.06 0.00000 
P342 17 41243509 BRCA1 NM_007294.3 c.4039A>G p.(Arg1347Gly) 0.6424 222 231 0.49 649 49 0.93 1.90 0.00000 
P211 13 32913062 BRCA2 NM_000059.3 c.4570T>G p.(Phe1524Val) 0.0018 443 500 0.47 59 586 0.09 0.19 0.00000 
P221 17 41246092 BRCA1 NM_007294.3 c.1456T>C p.(Phe486Leu) 0.0294 289 368 0.44 388 48 0.89 2.02 0.00000 
P221 17 41245900 BRCA1 NM_007294.3 c.1648A>C p.(Asn550His) 0.0295 358 358 0.50 532 66 0.89 1.78 0.00000 
P121 13 32937521 BRCA2 NM_000059.3 c.8182G>A p.(Val2728Ile) 0.3257 588 522 0.53 186 742 0.20 0.38 0.00000 
P211 13 32914592 BRCA2 NM_000059.3 c.6100C>T p.(Arg2034Cys) 0.4810 419 419 0.50 482 79 0.86 1.72 0.00000 
P243 13 32914592 BRCA2 NM_000059.3 c.6100C>T p.(Arg2034Cys) 0.4810 304 329 0.48 652 134 0.83 1.73 0.00000 
P384 13 32937488 BRCA2 NM_000059.3 c.8149G>T p.(Ala2717Ser) 0.1675 337 337 0.50 719 147 0.83 1.66 0.00000 
P243 17 41246812 BRCA1 NM_007294.3 c.736T>G p.(Leu246Val) 0.0394 326 313 0.51 124 606 0.17 0.33 0.00000 
P283 13 32930673 BRCA2 NM_000059.3 c.7544C>T p.(Thr2515Ile) 0.1012 466 504 0.48 60 401 0.13 0.27 0.00000 
P221 17 41251803 BRCA1 NM_007294.3 c.536A>G p.(Tyr179Cys) 0.0294 265 265 0.50 431 64 0.87 1.74 0.00000 
P400 17 41226488 BRCA1 NM_007294.3 c.4535G>T p.(Ser1512Ile) 0.3129 424 441 0.49 739 234 0.76 1.55 0.00000 
P196 17 41243512 BRCA1 NM_007294.3 c.4036G>A p.(Glu1346Lys) 0.0074 225 234 0.49 105 551 0.16 0.33 0.00000 
P412 17 41246812 BRCA1 NM_007294.3 c.736T>G p.(Leu246Val) 0.0394 340 340 0.50 318 61 0.84 1.68 0.00000 
P187 13 32906593 BRCA2 NM_000059.3 c.978C>A p.(Ser326Arg) 0.1039 271 282 0.49 502 125 0.80 1.63 0.00000 
P215 17 41244246 BRCA1 NM_007294.3 c.3302G>A p.(Ser1101Asn) 0.0184 396 396 0.50 29 211 0.12 0.24 0.00000 
P109 13 32893207 BRCA2 NM_000059.3 c.68-7T>A p.(?) 0.2918 130 102 0.56 17 188 0.08 0.15 0.00000 
P1 13 32914815 BRCA2 NM_000059.3 c.6323G>A p.(Arg2108His) 0.0818 230 230 0.50 189 709 0.21 0.42 0.00000 
P367 13 32953550 BRCA2 NM_000059.3 c.8851G>A p.(Ala2951Thr) 0.4400 113 138 0.45 210 26 0.89 1.98 0.00000 
P121 13 32907000 BRCA2 NM_000059.3 c.1385A>G p.(Glu462Gly) 0.0407 366 429 0.46 464 172 0.73 1.59 0.00000 
P405 13 32937521 BRCA2 NM_000059.3 c.8182G>A p.(Val2728Ile) 0.3257 236 245 0.49 501 141 0.78 1.59 0.00000 
P3 13 32914592 BRCA2 NM_000059.3 c.6100C>T p.(Arg2034Cys) 0.4810 287 336 0.46 420 147 0.74 1.61 0.00000 
P354 13 32953604 BRCA2 NM_000059.3 c.8905G>A p.(Val2969Met) 0.0663 125 125 0.50 319 52 0.86 1.72 0.00000 
P168 13 32914592 BRCA2 NM_000059.3 c.6100C>T p.(Arg2034Cys) 0.4810 258 268 0.49 327 87 0.79 1.61 0.00000 
P206 13 32972626 BRCA2 NM_000059.3 c.9976A>T p.(Lys3326*) 0.8407 432 416 0.51 138 394 0.26 0.51 0.00000 
P329 13 32913062 BRCA2 NM_000059.3 c.4570T>G p.(Phe1524Val) 0.0018 239 259 0.48 64 272 0.19 0.40 0.00000 
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P239 13 32914277 BRCA2 NM_000059.3 c.5785A>G p.(Ile1929Val) 0.0313 420 438 0.49 245 599 0.29 0.59 0.00000 
P362 13 32914839 BRCA2 NM_000059.3 c.6347A>G p.(His2116Arg) 0.0261 105 110 0.49 103 11 0.90 1.84 0.00000 
P333 13 32945172 BRCA2 NM_000059.3 c.8567A>C p.(Glu2856Ala) 0.1326 219 258 0.46 66 266 0.20 0.43 0.00000 
P367 17 41249263 BRCA1 NM_007294.3 c.591C>T p.(Cys197Cys) 0.1789 83 94 0.47 97 11 0.90 1.91 0.00000 
P364 13 32953550 BRCA2 NM_000059.3 c.8851G>A p.(Ala2951Thr) 0.4400 207 298 0.41 114 458 0.20 0.49 0.00000 
P68 13 32953549 BRCA2 NM_000059.3 c.8850G>T p.(Lys2950Asn) 0.0718 110 140 0.44 24 172 0.12 0.27 0.00000 
P4 13 32914592 BRCA2 NM_000059.3 c.6100C>T p.(Arg2034Cys) 0.4810 121 125 0.49 261 82 0.76 1.55 0.00000 
P330 17 41226488 BRCA1 NM_007294.3 c.4535G>T p.(Ser1512Ile) 0.3129 455 514 0.47 366 206 0.64 1.36 0.00000 
P393 13 32953549 BRCA2 NM_000059.3 c.8850G>T p.(Lys2950Asn) 0.0718 212 259 0.45 147 420 0.26 0.58 0.00000 
P253 13 32906593 BRCA2 NM_000059.3 c.978C>A p.(Ser326Arg) 0.1039 234 225 0.51 304 118 0.72 1.41 0.00000 
P128 17 41243509 BRCA1 NM_007294.3 c.4039A>G p.(Arg1347Gly) 0.6424 411 446 0.48 138 323 0.30 0.63 0.00000 
P52 17 41243509 BRCA1 NM_007294.3 c.4039A>G p.(Arg1347Gly) 0.6424 103 142 0.42 387 200 0.66 1.57 0.00000 
P53 17 41243509 BRCA1 NM_007294.3 c.4039A>G p.(Arg1347Gly) 0.6424 350 311 0.53 266 99 0.73 1.38 0.00000 
P22 13 32937521 BRCA2 NM_000059.3 c.8182G>A p.(Val2728Ile) 0.3257 269 303 0.47 120 45 0.73 1.55 0.00000 
P20 17 41243509 BRCA1 NM_007294.3 c.4039A>G p.(Arg1347Gly) 0.6424 120 130 0.48 102 32 0.76 1.58 0.00000 
P107 13 32937488 BRCA2 NM_000059.3 c.8149G>T p.(Ala2717Ser) 0.1675 335 322 0.51 263 129 0.67 1.31 0.00000 
P315 13 32972626 BRCA2 NM_000059.3 c.9976A>T p.(Lys3326*) 0.8407 216 224 0.49 49 131 0.27 0.55 0.00000 
P91 13 32906593 BRCA2 NM_000059.3 c.978C>A p.(Ser326Arg) 0.1039 224 263 0.46 172 383 0.31 0.67 0.00000 
P154 13 32930673 BRCA2 NM_000059.3 c.7544C>T p.(Thr2515Ile) 0.1012 352 447 0.44 139 85 0.62 1.41 0.00001 
P481 13 32972626 BRCA2 NM_000059.3 c.9976A>T p.(Lys3326*) 0.8407 310 310 0.50 126 65 0.66 1.32 0.00037 
P472 13 32937521 BRCA2 NM_000059.3 c.8182G>A p.(Val2728Ile) 0.3257 211 219 0.49 433 676 0.39 0.80 0.00122 
P54 13 32907129 BRCA2 NM_000059.3 c.1514T>C p.(Ile505Thr) 0.1079 198 190 0.51 354 217 0.62 1.22 0.00240 
P352 13 32945172 BRCA2 NM_000059.3 c.8567A>C p.(Glu2856Ala) 0.1326 125 125 0.50 134 72 0.65 1.30 0.00350 
P475 13 32912750 BRCA2 NM_000059.3 c.4258G>T p.(Asp1420Tyr) 0.8179 402 387 0.51 353 468 0.43 0.84 0.00382 
P445 13 32953550 BRCA2 NM_000059.3 c.8851G>A p.(Ala2951Thr) 0.4400 106 125 0.46 402 291 0.58 1.26 0.00463 
P398 17 41243509 BRCA1 NM_007294.3 c.4039A>G p.(Arg1347Gly) 0.6424 215 252 0.46 174 136 0.56 1.22 0.01750 
P317 17 41249263 BRCA1 NM_007294.3 c.591C>T p.(Cys197Cys) 0.1789 108 108 0.50 49 23 0.68 1.36 0.02391 
P300 13 32929007 BRCA2 NM_000059.3 c.7017G>C p.(Lys2339Asn) 0.0018 120 111 0.52 88 133 0.40 0.77 0.02762 
P449 13 32953550 BRCA2 NM_000059.3 c.8851G>A p.(Ala2951Thr) 0.4400 231 283 0.45 141 130 0.52 1.16 0.14920 
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P477 13 32945172 BRCA2 NM_000059.3 c.8567A>C p.(Glu2856Ala) 0.1326 189 196 0.49 78 113 0.41 0.84 0.15434 
P69 13 32930673 BRCA2 NM_000059.3 c.7544C>T p.(Thr2515Ile) 0.1012 118 133 0.47 78 61 0.56 1.19 0.26949 
P213 13 32972626 BRCA2 NM_000059.3 c.9976A>T p.(Lys3326*) 0.8407 382 352 0.52 98 116 0.46 0.88 0.28469 
P465 13 32972695 BRCA2 NM_000059.3 c.10045A>G p.(Thr3349Ala) 0.0018 340 301 0.53 413 311 0.57 1.08 0.33264 
P264 13 32906593 BRCA2 NM_000059.3 c.978C>A p.(Ser326Arg) 0.1039 126 142 0.47 154 222 0.41 0.87 0.34299 
P62 13 32937521 BRCA2 NM_000059.3 c.8182G>A p.(Val2728Ile) 0.3257 115 129 0.47 135 115 0.54 1.15 0.34833 
P434 13 32913562 BRCA2 NM_000059.3 c.5070A>C p.(Lys1690Asn) 0.0225 394 410 0.49 266 325 0.45 0.92 0.36327 
P246 13 32912750 BRCA2 NM_000059.3 c.4258G>T p.(Asp1420Tyr) 0.8179 232 222 0.51 324 366 0.47 0.92 0.41658 
P413 13 32912750 BRCA2 NM_000059.3 c.4258G>T p.(Asp1420Tyr) 0.8179 457 457 0.50 241 206 0.54 1.08 0.41589 
P300 13 32929309 BRCA2 NM_000059.3 c.7319A>G p.(His2440Arg) 0.0018 124 110 0.53 137 155 0.47 0.89 0.42197 
P392 13 32906766 BRCA2 NM_000059.3 c.1151C>T p.(Ser384Phe) 0.1049 285 309 0.48 417 510 0.45 0.94 0.58790 
P11 13 32907407 BRCA2 NM_000059.3 c.1792A>G p.(Thr598Ala) 0.3706 177 163 0.52 66 77 0.46 0.88 0.59444 
P44 13 32912750 BRCA2 NM_000059.3 c.4258G>T p.(Asp1420Tyr) 0.8179 269 269 0.50 335 377 0.47 0.94 0.65887 
P429 13 32914592 BRCA2 NM_000059.3 c.6100C>T p.(Arg2034Cys) 0.4810 205 240 0.46 253 336 0.43 0.93 0.73863 
P181 13 32953550 BRCA2 NM_000059.3 c.8851G>A p.(Ala2951Thr) 0.4400 257 290 0.47 698 726 0.49 1.04 0.88200 
P157 13 32907407 BRCA2 NM_000059.3 c.1792A>G p.(Thr598Ala) 0.3706 105 128 0.45 315 341 0.48 1.07 0.92371 
P236 13 32972626 BRCA2 NM_000059.3 c.9976A>T p.(Lys3326*) 0.8407 398 383 0.51 292 304 0.49 0.96 0.98840 
P108 13 32906766 BRCA2 NM_000059.3 c.1151C>T p.(Ser384Phe) 0.1049 375 423 0.47 299 311 0.49 1.04 0.99168 
P327 13 32953550 BRCA2 NM_000059.3 c.8851G>A p.(Ala2951Thr) 0.4400 169 191 0.47 300 313 0.49 1.04 1.11608 
P310 17 41219694 BRCA1 NM_007294.3 c.5005G>T p.(Ala1669Ser) 0.0055 206 297 0.41 161 214 0.43 1.05 1.16985 
P135 13 32907407 BRCA2 NM_000059.3 c.1792A>G p.(Thr598Ala) 0.3706 112 112 0.50 475 438 0.52 1.04 1.20733 
P324 13 32912750 BRCA2 NM_000059.3 c.4258G>T p.(Asp1420Tyr) 0.8179 123 123 0.50 157 145 0.52 1.04 1.31730 
P151 13 32912750 BRCA2 NM_000059.3 c.4258G>T p.(Asp1420Tyr) 0.8179 318 305 0.51 566 566 0.50 0.98 1.35494 
P488 13 32906766 BRCA2 NM_000059.3 c.1151C>T p.(Ser384Phe) 0.1049 447 504 0.47 259 280 0.48 1.02 1.37876 
P194 13 32912007 BRCA2 NM_000059.3 c.3515C>T p.(Ser1172Leu) 0.0975 270 304 0.47 551 597 0.48 1.02 1.40007 
P55 13 32912750 BRCA2 NM_000059.3 c.4258G>T p.(Asp1420Tyr) 0.8179 271 241 0.53 415 384 0.52 0.98 1.40524 
P196 13 32937521 BRCA2 NM_000059.3 c.8182G>A p.(Val2728Ile) 0.3257 278 289 0.49 395 395 0.50 1.02 1.41169 
P252 13 32953550 BRCA2 NM_000059.3 c.8851G>A p.(Ala2951Thr) 0.4400 259 269 0.49 201 201 0.50 1.02 1.49170 
P112 13 32906593 BRCA2 NM_000059.3 c.978C>A p.(Ser326Arg) 0.1039 225 287 0.44 84 103 0.45 1.02 1.62008 
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P300 13 32972380 BRCA2 NM_000059.3 c.9730G>A p.(Val3244Ile) 0.0018 115 134 0.46 168 189 0.47 1.02 1.62179 
P430 13 32953550 BRCA2 NM_000059.3 c.8851G>A p.(Ala2951Thr) 0.4400 86 109 0.44 141 180 0.44 1.00 1.85784 
P295 13 32906766 BRCA2 NM_000059.3 c.1151C>T p.(Ser384Phe) 0.1049 203 293 0.41 98 140 0.41 1.00 1.83981 
P272 13 32945172 BRCA2 NM_000059.3 c.8567A>C p.(Glu2856Ala) 0.1326 170 185 0.48 154 167 0.48 1.00 1.83092 
 
Supplementary Table 3: Performance of loss of heterozygosity (LOH)-analyses for the classification of rare germline variants in the BRCA1 and BRCA2 genes. Test for pathogenicity 
is based on the assumption that a significantly increased variant fraction in the tumour predicts pathogenicity.Test for benignity is based on the assumption that a significantly 
decreased variant fraction in the tumour predicts benignity. * = calculation was performed using the Haldane-Anscombe correction[1]. PPV = positive predictive value; LR+ = 
positive likelihood ratio. 
 BRCA1/2 (n=184) BRCA1 (n=88) BRCA2 (n=96) 
Test for pathogenicity    
Sensitivity (95%CI) 0.84 (0.75-0.91) 0.88 (0.78-0.95) 0.73 (0.52-0.88) 
Specificity (95%CI) 0.63 (0.53-0.73) 0.35 (0.15-0.59) 0.71 (0.59-0.82) 
PPV (95%CI) 0.71 (0.61-0.79) 0.82 (0.71-0.90) 0.49 (0.32-0.65) 
LR+ (95%CI) 2.29 (1.72-3.05) 1.36 (0.97-1.89) 2.56 (1.65-3.96) 
Test for benignity    
Sensitivity (95%CI) 0.26 (0.17-0.36) 0.30 (0.12-0.54) 0.24 (0.15-0.36) 
Specificity (95%CI) 1.00 (0.96-1.00) 1.00 (0.95-1.00) 1.00 (0.87-1.00) 
PPV (95%CI) 1.00 (0.85-1.00) 1.00 (0.54-1.00) 1.00 (0.80-1.00) 
LR+ (95%CI)* 49.07 (3.02-795.93) 42.71 (2.51-727.20) 13.31 (0.83-213.68) 
 
Reference: 
1. Haldane JB. The estimation and significance of the logarithm of a ratio of frequencies. Ann Hum Genet 1956;20(4):309-11 doi: 10.1111/j.1469-1809.1955.tb01285.x  
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